News summaryThe Motley FoolNov 5, 2026, 05:00 PM
Precigen (PGEN) Q3 2026 Earnings Call Transcript
Precigen management said PAPZIMEOS net product revenue was $72.9 million in the third quarter, up about 37% from the second quarter. [[fact:fact-2haa9wq4p]] Management also reported third-quarter net income of $35.8 million. [[fact:fact-eutvvyn85]] The company said it generated $11.9 million in cash from operating activities in the third quarter. [[fact:fact-pqyssz3lu]] Management said more than 500 patients had begun PAPZIMEOS treatment by the call date. [[fact:fact-g41y3lceu]]